MK-7264

MK-7264（英語：Gefapixant）是一種磺胺類藥物，作為嘌呤P2X受體P2RX3（英語：P2RX3）的拮抗劑，可用於治療慢性咳嗽（英語：chronic cough）^[1][2][3]。

MK-7264

法律規範狀態
法律規範	美：Investigational New Drug
識別資訊
IUPAC命名法 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS號	1015787-98-0  Y
PubChem CID	24764487
DrugBank	DB15097
ChemSpider	58828660
UNII	6K6L7E3F1L
KEGG	D11349
ChEMBL	ChEMBL3716057
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID401337212
ECHA InfoCard	100.258.106
化學資訊
化學式	C14H19N5O4S
摩爾質量	353.4
3D模型（JSmol（英語：JSmol））	交互式圖像
SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19) Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

參考文獻

1. Muccino D, Green S. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulmonary Pharmacology & Therapeutics. June 2019, 56 ( ): 75–78. PMID 30880151. doi:10.1016/j.pupt.2019.03.006.
2. Richards D, Gever JR, Ford AP, Fountain SJ. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. British Journal of Pharmacology. July 2019, 176 (13): 2279–2291. PMC 6555852 . PMID 30927255. doi:10.1111/bph.14677.
3. Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, Lambertucci C. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents. December 2019, 29 (12): 943–963. PMID 31726893. doi:10.1080/13543776.2019.1693542.